Atenolol / chlorthalidone Pregnancy and Breastfeeding Warnings
Brand names: Tenoretic, Tenoretic 100, Tenoretic 50
Medically reviewed by Drugs.com. Last updated on Aug 3, 2023.
Atenolol / chlorthalidone Pregnancy Warnings
UK: Use should be avoided.
US: Caution is recommended; benefit should outweigh risk.
.
US FDA pregnancy category: D
Comments: If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
Animal studies have revealed embryonic resorptions. Atenolol has been shown to produce a dose-related increase in embryofetal resorptions in rats. In humans, atenolol administration starting in the second trimester has been associated with the birth of infants that are small for gestational age. Controlled data in human pregnancy exists only for atenolol in the second and third trimesters of pregnancy.
US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Atenolol / chlorthalidone Breastfeeding Warnings
Use should be avoided.
Excreted into human milk: Yes (atenolol, chlorthalidone [chlortalidone])
See also
References for pregnancy information
- (2001) "Product Information. Tenoretic (atenolol-chlorthalidone)." Astra-Zeneca Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
References for breastfeeding information
- (2001) "Product Information. Tenoretic (atenolol-chlorthalidone)." Astra-Zeneca Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
